Microorganisms-derived antigens for preventive anti-cancer vaccines

被引:7
|
作者
Buonaguro, Luigi [1 ]
Cavalluzzo, Beatrice [1 ]
Mauriello, Angela [1 ]
Ragone, Concetta [1 ]
Tornesello, Anna Lucia [2 ]
Buonaguro, Franco M. [2 ]
Tornesello, Maria Lina [2 ]
Tagliamonte, Maria [1 ,3 ]
机构
[1] Ist Nazl Tumori IRCCS Fond G Pascale, Innovat Immunol Models Unit, Naples, Italy
[2] Ist Nazl Tumori IRCCS Fond G Pascale, Mol Biol & Viral Oncogenesis Unit, Naples, Italy
[3] Ist Nazl Studio & Cura Tumori, Fdn Pascale IRCCS, Lab Innovat Immunol Models, Via Mariano Semmola, 52, Naples, Italy
关键词
HEPATITIS-C VIRUS; ENVELOPE GLYCOPROTEIN GP340; CELLULAR IMMUNE-RESPONSES; HUMAN-PAPILLOMAVIRUS VACCINE; CD8(+) T-CELLS; PHASE-I TRIAL; B-VACCINE; COTTONTOP TAMARINS; HEPATOCELLULAR-CARCINOMA; RHESUS MACAQUES;
D O I
10.1016/j.mam.2023.101192
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer prevention is one of the aim with the highest priority in order to reduce the burden of cancer diagnosis and treatment on individuals as well as on healthcare systems.To this aim, vaccines represent the most efficient primary cancer prevention strategy. Indeed, anti-cancer immunological memory elicited by preventive vaccines might promptly expand and prevent tumor from progressing.Antigens derived from microorganisms (MoAs), represent the obvious target for developing highly effective preventive vaccines for virus-induced cancers. In this respect, the drastic reduction in cancer incidence following HBV and HPV preventive vaccines are the paradigmatic example of such evidence. More recently, experimental evidences suggest that MoAs may represent a "natural" anti-cancer preventive vaccination or can be exploited for developing vaccines to prevent cancers presenting highly homologous tumor-associated antigens (TAAs) (e.g. molecular mimicry).The present review describes the different preventive anti-cancer vaccines based on antigens derived from pathogens at the different stages of development.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Anti-cancer effect of COVID-19 vaccines in mice models
    Deldadeh, Negar
    Haghighat, Shahpar
    Omidi, Zahra
    Sarrami-Foroushani, Ramin
    Ansari, Alireza Madjid
    Sanati, Hassan
    Azizi, Azadeh
    Zayeri, Farid
    Forouzesh, Flora
    Geijtenbeek, Teunis B. H.
    Javidi, Mohammad Amin
    LIFE SCIENCES, 2023, 325
  • [32] Recent progress in immunotherapy: anti-cancer vaccines, emerging clinical data
    Dalgleish, A. G.
    ANNALS OF ONCOLOGY, 2008, 19 : 248 - 251
  • [33] Strategies for Anti-Cancer Immunotherapy Using Vaccines and Blockade of Negative Regulation
    Berzofsky, Jay A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 : 67 - 67
  • [34] NEW PLANT-DERIVED ANTI-CANCER DRUGS
    KINGHORN, AD
    PHARMACY INTERNATIONAL, 1983, 4 (07): : 191 - 191
  • [35] Preventive anti-HIV vaccines
    Pialoux, G
    Slama, L
    PRESSE MEDICALE, 2005, 34 (20): : 1592 - 1596
  • [36] Preventive vaccines for cervical cancer
    Wheeler, CM
    SALUD PUBLICA DE MEXICO, 1997, 39 (04): : 283 - 287
  • [37] The Promise of Preventive Cancer Vaccines
    Lollini, Pier-Luigi
    Cavallo, Federica
    Nanni, Patrizia
    Quaglino, Elena
    VACCINES, 2015, 3 (02): : 467 - 489
  • [38] Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy
    Almasi, Jannik
    Knoll, Laura
    Thiesen, Judith
    Kraemer, Irene
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (04) : 614 - 621
  • [39] Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Iero, Manuela
    Filipazzi, Paola
    Castelli, Chiara
    Belli, Filiberto
    Valdagni, Riccardo
    Parmiani, Giorgio
    Patuzzo, Roberto
    Santinami, Mario
    Rivoltini, Licia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (07) : 1159 - 1167
  • [40] Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Manuela Iero
    Paola Filipazzi
    Chiara Castelli
    Filiberto Belli
    Riccardo Valdagni
    Giorgio Parmiani
    Roberto Patuzzo
    Mario Santinami
    Licia Rivoltini
    Cancer Immunology, Immunotherapy, 2009, 58 : 1159 - 1167